US4849427A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nedocromil calcium and use thereof in treatment of reversible obstructive airways disease
Assignee: Fisons Ltd
•
Filing: 1988-02-24
•
Granted: 1989-07-18
•
Expires: 2008-02-24
Abstract
Abstract There are described a new compound, methods for its preparation and compositions containing it. Calcium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dicarboxylate is a novel compound and is useful in the treatment of reversible obstructive airways disease and/or the prevention or treatment of rhinitis.
Inventors
- 👤 Michael A. Nassim
- 👤 Richard A. Raphael
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:32
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/04; C07D491/044; C07D491/052; A; A61; A61P; A61P11/00; A61P11/08; A61P27/00; A61P27/16
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
2 words
Calcium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dicarboxylate.
Claim 2
Dependent Claim
2 words
Calcium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dicarboxylate.
Claim 3
Dependent Claim
16 words
The compound according to claim 1, wherein the water content is from 12 to 25% w/w.
Claim 4
Independent Claim
27 words
A method of treatment of reversible obstructive airways disease which comprises administering a therapeutically effective amount of nedocromil calcium to a patient suffering from such a condition.
Claim 5
Independent Claim
27 words
A method of treatment of reversible obstructive airways disease which comprises administering a therapeutically effective amount of nedocromil calcium to a patient suffering from such a condition.
Claim 6
Independent Claim
24 words
A method of treatment of rhinitis which comprises administering a therapeutically effective amount of nedocromil calcium to a patient suffering from such a condition.
Claim 7
Independent Claim
24 words
A method of treatment of rhinitis which comprises administering a therapeutically effective amount of nedocromil calcium to a patient suffering from such a condition.
Claim 8
Dependent Claim
30 words
A composition for treatment of reversible obstructive airways disease comprising an effective proportion of a compound according to claim 1 in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.
Claim 9
Dependent Claim
14 words
A composition in accordance with claim 5 in powder form for administration by inhalation.
Claim 10
Dependent Claim
18 words
A composition in accordance with claim 6 in a pressurized aerosol formulation in admixture with a liquefied propellant.
Claim 11
Dependent Claim
22 words
A composition in accordance with claim 7 wherein said compound of claim 1 has a water content of less than 5% w/w.
Claim 12
Dependent Claim
34 words
A method for treating reversible obstructive airways disease or rhinitis comprising administering an effective amount of the compound of claim 1 to a patient suffering or likely to be suffering from such a condition.
References Cited (Backward Citations)
GB2022078A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-17 | 1993-01-16 | 1993-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-17 | 1997-01-16 | 1997-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-17 | 2001-01-16 | 2001-07-18 | $7700.00 | Window Closed / Lapsed |